Future Oncology

Article	Citations
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation	128
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer	109
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811	105
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma withFGFR2rearrangements	94
Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities	72
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)	69
An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer	68
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA	65
The abscopal effect of radiation therapy	61
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer	60
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma	60
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy	59
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma	58
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer	58
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial	57
How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancer	56
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia	51
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma	50
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design	49
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC	44
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study	44
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer	43
Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis	42
Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing	41
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors	40

Organ tropism in solid tumor metastasis: an updated review	40
Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma	39
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer	39
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer	38
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)	38
Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials	36
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies	35
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma	34
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412	34
Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey	34
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma	33
CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies	33
Systemic therapy of advanced hepatocellular carcinoma	31
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma	31
GammaTile®: Surgically targeted radiation therapy for glioblastomas	31
Clinicopathological study of organ metastasis in endometrial cancer	31
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic	30
Oncolytic viruses: challenges and considerations in an evolving clinical landscape	28
Molecular avenues in targeted doxorubicin cancer therapy	28
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance	28
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer	27
Cancer and COVID-19: analysis of patient outcomes	27
Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors?	27
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer	27
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design	27
Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy	26
Current trends in the treatment of HR+/HER2+ breast cancer	26
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma	26
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer	25
GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway	25
A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma	25
Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases	24
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma	24
Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials	23
Oral health-related quality of life in oral cancer patients: systematic review and meta-analysis	23
Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis	23
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design	23
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)	23
Precision oncology: a clinical and patient perspective	22
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?	22
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases	22
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design	22
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study	22
Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination	22
How we treat Merkel cell carcinoma: within and beyond current guidelines	22
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor	22
The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic	22
The future of radiation-induced abscopal response: beyond conventional radiotherapy approaches	22
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303	21
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer	21

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design	21
Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test	21
A theoretical model of financial burden after cancer diagnosis	21
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer	21
The psychological challenges for oncological patients in times of COVID-19 pandemic: telemedicine, a solution?	20
Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress	20
First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis	20
DNA damage response alterations in gastric cancer: knocking down a new wall	20
Long noncoding RNA ANRIL as a novel biomarker in human cancer	20
Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment	19
EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma	19
Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 – what’s old is new again?	19
Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life	19
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial	19
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia	18
Surgery for pancreatic cancer: current controversies and challenges	18
Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy	18
Low preoperative serum ALB level is independently associated with poor overall survival in endometrial cancer patients	18
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis	18
Granulomatous prostatitis: a challenging differential diagnosis to take into consideration	18
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer	18
What is the alternative? Responding strategically to cancer misinformation	18
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma	18
Understanding patient factors to increase uptake of cancer screening: a review	18
Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers	18
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA	17
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma	17
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas	17
KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer	17
Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic	17
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need	17
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design	17
The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer	16
Trastuzumab deruxtecan for HER2+ advanced breast cancer	16
Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives	16
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer	16
Circulating serum exosomal miR-92a-3p as a novel biomarker for early diagnosis of gastric cancer	16
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma	16
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design	15
Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer	15
Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis	15
Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study	15
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study	15
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations	15
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications	15
The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment	15
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer	15
Current and potential biomarkers in gastric cancer: a critical review of the literature	15
Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer	15
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors	15
Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses	14
Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer	14
What the oncologist needs to know about COVID-19 infection in cancer patients	14
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia	14
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design	14
Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?	14
Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer	14
Molecular tests and target therapies in oncology: recommendations from the Italian workshop	14
Improvement strategies for successful next-generation sequencing analysis of lung cancer	14
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review	14
Prognostic value of systemic inflammatory marker in patients with head and neck squamous cell carcinoma undergoing surgical resection	14
A nomogram for predicting overall survival in patients with uterine leiomyosarcoma: a SEER population-based study	14
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol	14
Lurbinectedin in the treatment of relapsed small cell lung cancer	13
Management and outcomes of primary anorectal melanoma in the United States	13
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas	13
Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma	13
Predictive markers of immune response in glioblastoma: hopes and facts	13
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication	13
Metastatic lymph node ratio as a better prognostic tool than the TNM system in colorectal cancer	13
NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)	13
Discovering the first US FDA-approved computer-aided polyp detection system	13
CD38 as an immunomodulator in cancer	13
Immuno-oncology for esophageal cancer	13
Patient satisfaction with telemedicine for prechemotherapy evaluation during the COVID-19 pandemic	13
Cancer-associated fibroblasts of colorectal cancer and their markers: updates, challenges and translational outlook	13
Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer	13
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer	13
Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes	13
Pulmonary nodules precision localization techniques	13

Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia	13
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma	12
Prognostic implications of depression and inflammation in patients with metastatic lung cancer	12
Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma	12
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review	12
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma	12
Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis	12
A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas	12
Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA	12
Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study	12
Hematopoietic stem cell transplantation dilemma during the COVID-19 era	12
Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer	12
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA	12
Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer	12
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis	12
Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?	12
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer	12
Excellent diagnostic performance of FNA-Tg in detecting lymph nodes metastases from papillary thyroid cancer	12
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer	12
Pattern of breast cancer presentation during the COVID-19 pandemic: results from a cohort study in the UK	12
Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index	12
Upregulated expression of MTFR2 as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis	12
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma	11
Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia	11
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer	11
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1	11
How we treat HR-positive, HER2-negative early breast cancer	11
Development and validation of nomograms for epithelial ovarian cancer: a SEER population-based, real-world study	11
Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice	11
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer	11
PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion	11
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy	11
The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma	11
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)	11
A call to action: Antiracist patient engagement in adolescent and young adult oncology research and advocacy	11
Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences	11
Copanlisib in the treatment of non-Hodgkin lymphoma	11
Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma	11
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy	11
Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan	11
Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS	11
Use of real-world evidence for oncology clinical decision making in emerging economies	11
Treatment patterns and clinical outcomes of palbociclib-based therapy received in US community oncology practices	11
The interplay between dietary factors, gut microbiome and colorectal cancer: a new era of colorectal cancer prevention	11
Implementing multidisciplinary tumor boards in oncology: a narrative review	10
Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma	10
Telehealth amid the COVID-19 pandemic: perception among Asian, Native Hawaiian and Pacific Islander cancer patients	10
Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy	10
Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review	10
Pragmatic patient engagement in designing pragmatic oncology clinical trials	10
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma	10
Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study	10
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib	10
Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data	10
Single agent VS-6766 or VS-6766 plus defactinib inKRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial	10
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis	10
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial	10
Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer	10
CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma	10
Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC	10
PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer	10
The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience	10
Integrative analyses identify a DNA damage repair gene signature for prognosis prediction in lower grade gliomas	10
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma	10
Predicting occult lymph node metastasis by nomogram in patients with lung adenocarcinoma ≤2 cm	10
B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine	10
Rituximab biosimilars in hematologic malignancies: the need for a real-world approach	10
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges	10
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies	10
Acute myeloid leukemia transformed to a targetable disease	10
Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review	10
Defining treatment regimens and lines of therapy using real-world data in oncology	9
POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer	9
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma	9
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations	9
Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer	9
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients	9
Prognostic significance of baseline neutrophil–lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data	9
Bidirectional deep neural networks to integrate RNA and DNA data for predicting outcome for patients with hepatocellular carcinoma	9
Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis	9
Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA	9
Plasma exosomalmiR-1260a, miR-7977andmiR-192-5pas diagnostic biomarkers in epithelial ovarian cancer	9
The future of cancer research after COVID-19 pandemic: recession?	9
Plain Language Summary of Publication articles: helping disseminate published scientific articles to patients	9
Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review	9
Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany	9
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis	9
TRIM58 is a prognostic biomarker remodeling the tumor microenvironment in KRAS-driven lung adenocarcinoma	9
Analysis of differential metabolites in lung cancer patients based on metabolomics and bioinformatics	9
Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer	9
Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma	9
Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel	9
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma	9
Oral submucous fibrosis and heterogeneity in outcome measures: a critical viewpoint	8
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer	8